Ginkgo Bioworks Holdings Inc. Class A Common Stock Q2 2025 Earnings Recap

Ginkgo Bioworks reported a significant reduction in cash burn and costs, achieving a $250 million annual run rate savings three months ahead of schedule while guiding for continued revenue growth in 2025.

Key Takeaways

• Cell Engineering revenue increased by 8% year-over-year to $39 million, with a 10% rise in revenue-generating programs.
• Total adjusted EBITDA improved by 72%, reducing losses to $28 million from $99 million a year ago.
• Successful restructuring resulted in a 63% decrease in R&D expenses and a 57% drop in G&A expenses.
• Cash burn was reduced to $38 million, down from $110 million in the same quarter last year, enabling a stronger cash position of $474 million.
• Full-year revenue guidance for 2025 remains unchanged, with expectations of $167 million to $187 million, reflecting strategic growth initiatives.